8-K: Recursion Pharma Unveils Strong AI Drug Progress

Recursion Pharmaceuticals presented an updated investor presentation at the JP Morgan Healthcare Conference, highlighting progress in its AI-native drug discovery platform and clinical pipeline, including positive REC-4881 FAP data.

Summary

• Presented an updated investor presentation at the JP Morgan Healthcare Conference on January 12, 2026, detailing advancements in its AI-native drug discovery platform.
• Reported $755 million in cash, cash equivalents, and restricted cash as of December 31, 2025, providing an expected runway through year-end 2027.
• Achieved over $500 million in upfront and milestones from partnerships with potential for over $300 million plus double-digit royalties per program.
• The wholly-owned clinical pipeline includes approximately 5 programs, with about 15 programs in discovery.
• REC-4881 (MEK1/2 inhibitor) for Familial Adenomatous Polyposis (FAP) demonstrated rapid and durable polyp burden reduction (43% median at Week 13, 53% median at Week 25) with a safety profile consistent with MEK1/2 inhibition.
• The Sanofi partnership achieved 4 milestones for AI-designed molecules, and the Roche and Genentech partnership delivered 6 AI-powered biology maps, including two neuroscience maps.
• Expected 2026 cash burn is less than $390 million, representing a ~35% reduction in pro forma operating expenses from 2024 to 2026.
• The company's portfolio was focused to approximately 5 clinical programs as of May 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for REC-4881, significant partnership milestones, a robust cash position with extended runway, and clear operational efficiency improvements. The validation of the AI platform through clinical proof-of-concept and partner achievements indicates strong progress and future potential, outweighing the inherent risks of drug development.

Positives

• Achieved the first clinical proof-of-concept for Recursion's platform with REC-4881 in FAP, showing meaningful and durable polyp reduction (43% median at Week 13, 53% median at Week 25) and a safety profile consistent with its class.
• Maintained a strong cash position of $755 million as of year-end 2025, providing an expected cash runway through year-end 2027.
• Secured over $500 million in upfront and milestones from partnerships, with potential for over $300 million plus double-digit royalties per program.
• Successfully delivered 6 AI-powered biology maps to Roche and Genentech, including two groundbreaking neuroscience maps, and achieved 4 program milestones with Sanofi for AI-designed molecules.
• Demonstrated significant operational efficiency with an expected 2026 cash burn of less than $390 million, representing a ~35% reduction in pro forma operating expenses from 2024 to 2026.
• The proprietary AI-native end-to-end platform (Recursion OS) is effectively advancing drug discovery and clinical development, leveraging BioHive-2, described as the fastest, most powerful supercomputer wholly-owned and operated by a pharma or biotech company.
• REC-4881 has received Orphan Drug Designation (ODD) in the US and EU, and Fast Track Designation (FTD) in the US.

Risks

• Statements regarding the ability to use AI to translate complex science into medicines faster and better are forward-looking and subject to uncertainties.
• The amount and timing of potential milestone payments, cash position, and cash runway are estimates and depend on future events.
• The occurrence or realization of potential milestones from partnerships is not guaranteed.
• Current and future preclinical and clinical studies, including timelines for enrollment, data readouts, progression toward IND-enabling studies, and engagement with the FDA, are subject to inherent risks and uncertainties.
• Advancements of and other decisions regarding the pipeline, partnerships, and data strategies may not proceed as anticipated.
• The potential size of the market opportunity for drug candidates is an estimate and may not materialize as projected.
• Outcomes and benefits from licenses, partnerships, and collaborations, including option exercises by partners, are not guaranteed.
• The initiation, timing, progress, results, and cost of research and development programs are subject to various risks.
• The ability to identify viable new drug candidates for clinical development and the accelerating rate at which such candidates are identified, including leveraging acquired datasets, is a forward-looking statement.
• Cross-trial or cross-candidate comparisons against other clinical trials and drug candidates are not based on head-to-head studies and are presented for informational purposes, relying on publicly available information.

Future Outlook

Recursion Pharmaceuticals expects to advance clinical validation for REC-4881, optimize its dosing schedule, and define an FDA-aligned registrational study plan. The company anticipates approximately 5 programs entering or in trials with upcoming go/no-go decisions and aims to deliver differentiated programs with partners. Further, it plans to advance programs to late-discovery value inflection points and translate biology maps into new, partner-accepted discovery programs. Financially, the company projects a cash runway through year-end 2027 with an an expected 2026 cash burn of less than $390 million.

Management Comments

• "Maintaining ambition while raising the bar."
• "Our mission: Decoding biology to radically improve lives."
• "What we built: A unified, AI-native intelligence platform that translates complex science into medicines that matter – faster, better, and at scale for the patients who are waiting."
• "Leading the evolution of how medicines are discovered and delivered."
• "How we will create impact – with focus and discipline: Translate insights to proof points to new medicines; Empower exceptional, bilingual teams to deliver impact and humanity; Pair bold ambition with disciplined execution."

Industry Context

Recursion Pharmaceuticals is positioned at the forefront of integrating AI and machine learning into drug discovery and development, a significant trend in the pharmaceutical industry aimed at increasing efficiency, reducing costs, and accelerating the identification of novel therapeutics. Its focus on orphan diseases like FAP, where there are no approved pharmacotherapies, addresses a high unmet medical need, aligning with a growing industry emphasis on specialized treatments. The partnerships with major pharmaceutical companies like Roche, Genentech, and Sanofi validate its AI platform's potential and reflect a broader industry movement towards external innovation and leveraging advanced technologies. The use of a wholly-owned supercomputer, BioHive-2, underscores the capital-intensive and technologically advanced nature of this segment of the biotech industry.

Comparison to Industry Standards

• REC-4881 for FAP addresses a significant unmet need with no approved pharmacotherapies, positioning it favorably against the current standard of care which relies on surgery and endoscopic surveillance.
• The company's AI-driven generative design process achieves ~330 compounds to an advanced candidate in ~17 months on average, significantly faster and more efficient than the industry average of over 2,500 compounds and 42 months.
• AI-powered clinical development applications are projected to increase eligible patient populations by 10-40% and improve enrollment rates by ~1.5X, which are substantial improvements compared to traditional clinical trial recruitment methods.
• The BioHive-2 supercomputer is described as the "fastest, most powerful supercomputer wholly-owned and operated by a pharma or biotech company," indicating a leading position in computational infrastructure within the industry.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, significant partnership milestones, extended cash runway, and demonstrated operational efficiency, potentially increasing investor confidence and share value.
• Patients (FAP): Highly positive impact with REC-4881 showing promising results in an orphan disease with no approved pharmacotherapies, offering a potential new treatment option.
• Employees: Positive impact from continued progress, strong financial health, and validation of the company's AI platform, fostering job security and growth opportunities.
• Partners (Roche, Genentech, Sanofi): Continued successful collaboration and achievement of milestones reinforce the value of their partnerships with Recursion's AI platform.
• Creditors: Strong cash position and extended runway reduce credit risk.

Next Steps

• Engage with FDA for REC-4881 (MEK1/2i) in 1H 2026 to define registrational study plan.
• Obtain mono early safety and PK data for REC-1245 (RBM39 degrader) in 1H 2026.
• Start Phase 1 trial for REC-4539 (LSD1i) in 1H 2026.
• Make go/no-go decisions for REC-7735 (PI3K H1047Ri) and REC-102 (ENPP1i) in 2H 2026.
• Obtain additional clinical data for REC-4881 (MEK1/2i) in 1H 2027.
• Obtain combo early safety and PK data for REC-617 (CDK7i) in 1H 2027.
• Obtain Phase 1 data for REC-3565 (MALT1i) in 1H 2027.
• Obtain mono early safety and PK data for REC-4539 (LSD1i) in 2H 2027.
• Continue advancement of multiple neuroscience insights into target validation with Roche and Genentech.
• Advance Sanofi programs to lead optimization and development-candidate milestones.
• Anticipate multiple new project initiations with partners.
• Further develop biology foundation models and patient data for scalable, high-quality target discovery.
• Advance generative AI design at scale (next-gen models and agentic systems).
• Deploy Clinical Development AI at scale.

Key Dates

Recommendation

The filing provides compelling evidence of Recursion's progress and potential. The positive clinical proof-of-concept for REC-4881 in FAP, an orphan disease with high unmet need, is a significant de-risking event and validates the company's AI platform. Achieving over $500 million in partnership milestones and securing a cash runway through year-end 2027, coupled with a substantial reduction in cash burn, demonstrates strong financial management and external validation. The advanced AI capabilities and robust pipeline, with multiple upcoming catalysts, position Recursion for continued growth and value creation. These factors collectively suggest a strong investment opportunity.

Keywords

AI drug discovery, biotechnology, pharmaceuticals, precision medicine, Familial Adenomatous Polyposis, FAP, MEK1/2 inhibitor, REC-4881, clinical trials, oncology, neuroscience, Sanofi partnership, Roche Genentech partnership, supercomputer, BioHive-2, transcriptional foundation model, generative chemistry, clinical development AI, RXRX, investor presentation